DPYSL2, dihydropyrimidinase like 2, 1808

N. diseases: 93; N. variants: 6
Disease: Neuralgia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE Emerging evidence suggests that collapsin response mediator protein 2 (CRMP2) regulates presynaptic excitatory neurotransmission and contributes to pathological changes during diseases, such as neuropathic pain and substance use disorders. 31359322 2020
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 GeneticVariation phenotype BEFREE ST2-104, a nona-arginine (R9)-conjugated CBD3 peptide derived from CRMP2, exerts a beneficial effect on neuropathic pain; however, the effect of ST2-104 on AD and its mechanism of action have not been studied. 30871964 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE Future studies pursuing CRMP2 druggability in neuropathic pain will benefit from the findings that CRMP2 regulates only the N-type (CaV2.2) calcium channels. 31025580 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE A 15-amino-acid peptide (CBD3), derived from CRMP2, disrupts the functional protein-protein interaction between CRMP2 and Ca<sub>v</sub> 2.2 channels to inhibit calcium influx, transmitter release and acute, inflammatory and neuropathic pain. 28161890 2018
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 GeneticVariation phenotype BEFREE Spinal administration of a SUMOylation incompetent CRMP2 (CRMP2 K374A) significantly attenuated pain behavior in the spared nerve injury (SNI) model of neuropathic pain, underscoring the importance of SUMOylation of CRMP2 as a pathologic event in chronic pain. 30081699 2018
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE Structural modeling has now identified a pocket-harboring CRMP2's SUMOylation motif that, when targeted through computational screening of ligands/molecules, is expected to identify small molecules that will biochemically and functionally target CRMP2's SUMOylation to reduce NaV1.7 currents and reverse neuropathic pain. 29847471 2018
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE We examined plasma from SCI patients for autoantibodies to glial fibrillary acidic protein (GFAP) and collapsin response mediator protein-2 (CRMP2) and evaluated their relationship to the development of neuropathic pain. 29774780 2018
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE Changes in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to calcium channels blocked neuropathic pain. 26077693 2015
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.090 Biomarker phenotype BEFREE We identified an anti-nociceptive peptide (Brittain, J. M., Duarte, D. B., Wilson, S. M., Zhu, W., Ballard, C., Johnson, P. L., Liu, N., Xiong, W., Ripsch, M. S., Wang, Y., Fehrenbacher, J. C., Fitz, S. D., Khanna, M., Park, C. K., Schmutzler, B. S., Cheon, B. M., Due, M. R., Brustovetsky, T., Ashpole, N. M., Hudmon, A., Meroueh, S. O., Hingtgen, C. M., Brustovetsky, N., Ji, R. R., Hurley, J. H., Jin, X., Shekhar, A., Xu, X. M., Oxford, G. S., Vasko, M. R., White, F. A., and Khanna, R. (2011) Suppression of inflammatory and neuropathic pain by uncoupling CRMP2 from the presynaptic Ca(2+) channel complex.Nat.Med. 22891239 2012